Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order.
The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms.
As part of a settlement deal, Siemens will pay Enzo an upfront fee of $9.5 million and potentially up to $5 million in licensing royalties.
GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.
Myriad and Quest have agreed to dismiss lawsuits, claims, counterclaims, and disputes related to Myriad's patent claims on BRCA1 and BRCA2 in the litigation.
NEW YORK (GenomeWeb) – CareDx said after the close of the market on Wednesday that it has settled a dispute with Roche over a licensing agreement forged between the two firms in late 2004.
Just days before they were scheduled to go to trial, Alnylam Pharmaceuticals and Tekmira Pharmaceuticals announced that they have hammered out a settlement to their protracted patent-infringement and technology-misappropriation lawsuits.
NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has reached a settlement and licensing agreement with GeneSeek, resolving a patent dispute between the firms.
Cancer researcher Alan Rabson has died at 92, the New York Times reports.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.
The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.